FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer
Go back to FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer| Pfizer Inc. (NYSE: PFE) | Delayed: 28.45 -0.36 (1.25%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.81 | 52 Week High | $37.39 | |||
| Open | $28.58 | 52 Week Low | $28.25 | |||
| Day High | $28.69 | P/E | 17.24 | |||
| Day Low | $28.38 | EPS | $1.65 | |||
| Volume | 23,790,788 | |||||
